Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study

Jing Wang, Siqi Li, Hao Jiang, Ying-Jun Chang, Xiao-su Zhao, Jinsong JIA, Xiaolu Zhu, Lizhong Gong, Xiaohong Liu, Wen-Jing Yu, Xiaojun Huang

Blood (2023) 142 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2023-174600

Published: 2023

Journal Articles

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Wenbing Duan, Jinsong Jia, Jing Wang, Xiaohong Liu, Lizhong Gong, WenJing Yu, Xiaolu Zhu, Zhao Ting, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Yu Wang, Hongxia Shi, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2023-184769

Published: 2023

Journal Articles

Interferon-α-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia----a Prospective, Single-Arm Study

Xiaohong Liu, Yao Li, Wenjing Yu, Xiaolu Zhu, Jinsong Jia, Lizhong Gong, Xiaosu Zhao, Yingjun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2022) 140 (Supplement 1): 3299–3300.

https://doi.org/10.1182/blood-2022-168422

Published: 2022

Journal Articles

The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study

Hao Jiang, Jing Liu, Xiaohong Liu, Jinsong Jia, Lizhong Gong, Shengye Lu, Xiaojun Huang, Jing Wang, Xiaosu Zhao, Yueyun Lai, Hongxia Shi, Yingjun Chang, Guorui Ruan

Blood (2021) 138 (Supplement 1): 2320.

https://doi.org/10.1182/blood-2021-149493

Published: 2021

Journal Articles

Safety and Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single Institution Experience

Wen-Jing Yu, Jinsong JIA, Jing Wang, Fei-Fei Tang, Lizhong Gong, Xiaohong Liu, Xiaolu Zhu, Xiaosu Zhao, Xiao Jun Huang, Hao Jiang

Blood (2021) 138 (Supplement 1): 4413.

https://doi.org/10.1182/blood-2021-148259

Published: 2021

Journal Articles

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Jing Wang, MD, Jinsong Jia, Xiaohong Liu, Lizhong Gong, Shengye Lu, Yu Wang, Lanping Xu, Xiaohui Zhang, Chenhua Yan, Yueyun Lai, Xiaosu Zhao, PhD, Yazhen Qin, Guorui Ruan, Yingjun Chang, Hongxia Shi, Kaiyan Liu, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140977

Published: 2020

Journal Articles

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Wenbing Duan, Xiaohong Liu, Jinsong JIA, MDPhD, Jing Wang, MD, Lizhong Gong, Qian Jiang, MD, Ting Zhao, Yu Wang, Xiaohui Zhang, Lanping Xu, Xiaosu Zhao, PhD, Yazhen Qin, Hongxia Shi, Yingjun Chang, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141905

Published: 2020

Journal Articles

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Xiaohong Liu, Wenbing Duan, Jing Wang, MD, Jinsong Jia, Lizhong Gong, Shen-ye Lu, MD, Xiaosu Zhao, PhD, Ying-Jun Chang, Yue-Yun Lai, Hongxia Shi, Yu Wang, Chenhua Yan, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 3823.

https://doi.org/10.1182/blood-2019-128505

Published: 2019

Journal Articles

The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Wenbing Duan, Jinsong Jia, Jing Wang, MD, Xiaohong Liu, Lizhong Gong, Qian Jiang, MD, Ting Zhao, Yu Wang, Xiaohui Zhang, MD, Lanping Xu, Yanrong Liu, Yazhen Qin, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 2616.

https://doi.org/10.1182/blood-2019-126938

Published: 2019

Journal Articles

Observation on the Efficacy of Consolidation Chemotherapy Combined with Allogeneic Natural Killer Cell Infusion in the Treatment of Low and Moderate Risk AML

Hao Jiang, Xiaojun Huang, Chunjian Wang, Lizhong Gong, Jinsong Jia, Xiaohong Liu, Yu Wang, Chenhua Yan, Yingjun Chang, Xiaosu Zhao, PhD, Hongxia Shi

Blood (2019) 134 (Supplement_1): 1378.

https://doi.org/10.1182/blood-2019-122875

Published: 2019

Journal Articles

Clinical Features and Early Effect in EVI1 Positive Acute Myeloid Lleukemia

Wenbing Duan, Lizhong Gong, Jinsong Jia, Honghu Zhu, MD, Xiaosu Zhao, Qian Jiang, PhD, Ting Zhao, Ya-Zhen Qin, Xiaojun Huang, MD, Hao Jiang, MD

Blood (2017) 130 (Supplement 1): 5026.

https://doi.org/10.1182/blood.V130.Suppl_1.5026.5026

Published: 2017

NARROW

Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Interferon-α-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia----a Prospective, Single-Arm Study

The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study

Safety and Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single Institution Experience

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Observation on the Efficacy of Consolidation Chemotherapy Combined with Allogeneic Natural Killer Cell Infusion in the Treatment of Low and Moderate Risk AML

Clinical Features and Early Effect in EVI1 Positive Acute Myeloid Lleukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only